Earnings season is upon us; Makary on rare disease; Startup is first to...
Welcome back to Endpoints Weekly! Our team of reporters covered first-quarter earnings results from a handful of companies this week. See below for pharma executives’ comments on tariff exposure,...
View ArticleJ&J reports durability data for bladder cancer 'pretzel' drug
Johnson & Johnson said its drug-device combo for bladder cancer achieved a high rate of complete responses lasting at least a year, according to the latest data cut from a registrational trial....
View ArticleScholar Rock names new CEO, adds biotech veterans in C-suite rebuild
As it awaits an FDA approval decision, Scholar Rock is reshaping its leadership team with industry veterans. Current CEO Jay Backstrom is departing the Cambridge, MA-based drug developer in a "planned...
View ArticleBiohaven gets an up to $600M investment; Prilenia, Ferrer make a deal in Europe
Plus, #AUA2025 news from Protara Therapeutics, Pfizer, CG Oncology, and UroGen, in addition to the latest updates from Spruce Biosciences and Rezolute: Biohaven’s up to $600M financing deal: The...
View ArticleWuXi AppTec sees revenue growth after 2024’s decline
WuXi AppTec’s revenue rose for the first few months of 2025, signaling that pressures from the proposed Biosecure Act may be subsiding even as the threat of pharma tariffs remains. The CDMO pulled in...
View ArticleNovavax responds to FDA's request for new Covid vaccine trial
Novavax said it's responded to the FDA's request for a new clinical trial post-approval of the company's Covid-19 vaccine, following a report that the agency asked for a randomized study that could...
View ArticleBill cutting tax deductions for drug ads could help fund 'pill penalty' fix
A bipartisan piece of legislation proposed this week would prohibit pharma companies from receiving tax deductions for direct-to-consumer drug advertising, a bill that could generate savings to offset...
View ArticleVaxart says stop-work order was lifted on next-gen Covid vaccine
Vaxart said a stop-work order has been lifted on its next-generation Covid-19 vaccine efforts planned under a Biden-era initiative, allowing it to screen participants for a large mid-stage trial to...
View ArticleOctagon Therapeutics shuts down after 'unresolved biology questions'
Octagon Therapeutics is winding down operations, its CEO posted on LinkedIn on Monday. The biotech, with operations in Cambridge, MA, and Providence, RI, had been working on programs in autoimmune and ...
View ArticleFDA delays decision date for small biotech, raising questions about impact of...
The fate of a small, privately-held biotech’s new drug has been delayed, in what appears to be a sign that broad cuts to the FDA by the Trump administration may be affecting key regulatory decisions ...
View ArticleNovartis Q1 earnings: Company raises 2025 bar after beating sales expectations
Novartis is starting the year on a strong note as several of its core medicines beat Wall Street’s sales projections, prompting the drugmaker to shift its full-year guidance to a higher bar. In the...
View ArticleAstraZeneca posts another Truqap study fail, says China import tax could triple
AstraZeneca’s Truqap is 2-for-4 in its pivotal cancer trials. It said it was shutting down a Phase 3 Truqap study in a hard-to-treat form of prostate cancer after an interim analysis ...
View ArticleBasil Systems raises $11.5M to help pharma navigate regulations
A startup built to help pharmaceutical and medical device companies make sense of regulatory requirements just raised $11.5 million in new funding, Endpoints News has learned exclusively. Launched in...
View ArticlePfizer plans more cost cuts, expanding total savings to $7.7B
Pfizer is expanding its multibillion-dollar cost-cutting effort that began in 2023, announcing $1.7 billion in new planned reductions. The new round of cuts disclosed Tuesday is part of Pfizer’s "cost...
View ArticleAstraZeneca, Novartis execute ‘US for US’ strategy as pharma tariffs near
With the industry on tenterhooks on what the pharma-specific tariffs may look like, AstraZeneca and Novartis said Tuesday that their local production capacity will be key in sidestepping these levies....
View ArticleHims and Novo Nordisk partner to offer discounted Wegovy
In an unlikely partnership between two rivals, Hims & Hers said its members will now be able to get Novo Nordisk’s weight loss drug Wegovy at a discounted price directly through the telehealth...
View ArticleDevoted Health 2024 financials reveal revenue growth
Health insurance startup Devoted Health is a bright spot in the volatile market for private health plans for seniors, growing membership and revenue while narrowing its operating losses in 2024, even...
View ArticleWith a new CEO, oligonucleotide biotech Creyon forges Eli Lilly partnership
Creyon Bio, a small San Diego biotech startup working on oligonucleotides, has signed up Eli Lilly as its first big pharma partner. The Indianapolis giant, which has placed more of an emphasis on...
View ArticleAbbVie’s Rinvoq is approved in giant cell arteritis; Relmada shares bladder...
Plus, news about the Novo Nordisk Foundation and Tonix: AbbVie’s Rinvoq gets label expansion: The blockbuster JAK inhibitor won approval in the US to treat adults with giant cell arteritis, an ...
View ArticleFDA won't reorganize medical product centers, Makary says in interview
The FDA plans to consolidate some administrative functions, but won't embark on a wholesale reorganization of the review centers that oversee drugs, biologics and medical devices, FDA Commissioner...
View Article